抑制瘢痕细胞中串珠素表达对Ⅰ型胶原蛋白生成量的影响

目的：硬膜外瘢痕,又叫硬膜外纤维化,是指在硬膜外腔的手术涉及范围内形成的瘢痕组织或纤维化,是机体对创伤的修复反应。瘢痕的粘连和收缩会牵拉硬膜和神经根,限制其活动,被瘢痕包绕的神经根受到非正常的牵拉和挤压,神经纤维的轴浆运输、动脉血供、静脉回流受阻,神经根和背侧神经节对机械压迫很敏感,会产生一系列症状,如疼痛、麻木及下肢肌力降低等。近年来,对硬膜外瘢痕防治的研究大多是椎板切除术后如何通过物理或化学屏障来减少术后因瘢痕粘连导致的并发症。但对通过瘢痕形成过程中抑制其主要构成成分的生成来减轻椎板切除术后硬膜外瘢痕形成的相关研究还较少。通过减少椎板切除术后硬膜外瘢痕主要成分Ⅰ型胶原蛋白的生成来实现抑制椎板切除术后硬膜外瘢痕的形成。方法：选用30只250克两月鼠龄的SD雄性大鼠随机按1、2、3、4、5、6周分为6组,行后路4、5腰椎全椎板切除术。术后1、2、3、4、5、6周时每周取一组大鼠全锥板切除术后硬膜后方瘢痕组织,分别行病理切片HE染色,组织块贴壁法细胞培养。筛选第三周瘢痕组织培养的成纤维细胞进行慢病毒干扰串珠素表达并设对照组,通过Western-blot、RT-PCR分析Ⅰ型胶原蛋白生成量与对照组的差别并进行统计学分析。结果：慢病毒干扰小组Ⅰ型胶原蛋白生成量较对照组及纯病毒组明显减少（RT-PCR F=509.331,q A,B=-43.371,P〈0.01,q A,C=-46.133,P〈0.01,Western-Blot F=337.578;q A,B=-112.433,P〈0.01,q A,C=-89.227,P〈0.01）。结论：干扰串珠素表达能有效减少术后硬膜外瘢痕成纤维细胞生成Ⅰ型胶原蛋白,对抑制椎板切除术后硬膜外瘢痕形成应有一定作用。通过慢病毒介导的shRNA干扰成纤维细胞中的串珠素后,其生成的Ⅰ型胶原蛋白量与对照组相比较差异有统计学意义（P〈0.05）,这说明通过抑制瘢痕成纤维细胞的串珠素表达能够有效减少Ⅰ型胶原蛋白的生成。这种方法不论从Ⅰ型胶原蛋白是瘢痕主要构成成分方面,还是Ⅰ型胶原蛋白在瘢痕生成过程中分泌胶原中占得比例增多导致机体由胎儿期的无瘢痕愈合转化至成体的瘢痕愈合这个方面来将,理论上都能够做到有效地抑制、减少硬膜外瘢痕的形成,因此通过干扰硬膜外成纤维细胞串珠素表达从而达到抑制硬膜外瘢痕的形成这一理论是可行的,为进一步进行椎板切除术后抑制硬膜外瘢痕形成的体内试验奠定了理论基础。     

Drosophila perlecan modulates FGF and hedgehog signals to activate neural stem cell division

Mutations in the Drosophila trol gene cause cell cycle arrest of neuroblasts in the larval brain. Here, we show that trol encodes the Drosophila homolog of Perlecan and regulates neuroblast division by modulating both FGF and Hh signaling. Addition of human FGF-2 to trol mutant brains in culture rescues the trol proliferation phenotype, while addition of a MAPK inhibitor causes cell cycle arrest of the regulated neuroblasts in wildtype brains. Like FGF, Hh activates stem cell division in the larval brain in a Trol-dependent fashion. Coimmunoprecipitation studies are consistent with interactions between Trol and Hh and between mammalian Perlecan and Shh that are not competed with heparin sulfate. Finally, analyses of mutations in trol, hh, and ttv suggest that Trol affects Hh movement. These results indicate that Trol can mediate signaling through both of the FGF and Hedgehog pathways to control the onset of stem cell proliferation in the developing nervous system.     

UNC-52/perlecan affects gonadal leader cell migrations in C. elegans hermaphrodites through alterations in growth factor signaling

The unc-52 gene of Claenorhabditis elegans encodes a homologue of the basement membrane heparan sulfate proteoglycan perlecan. Viable alleles reduce the abundance of UNC-52 in late larval stages and increase the frequency of distal tip cell (DTC) migration defects caused by mutations disrupting the UNC-6/netrin guidance system. These unc-52 alleles do not cause circumferential DTC migration defects in an otherwise wild-type genetic background. The effects of unc-52 mutations on DTC migrations are distinct from effects on myofilament organization and can be partially suppressed by mutations in several genes encoding growth factor-like molecules, including EGL-17/FGF, UNC-129/TGF-beta, DBL-1/TGF-beta, and EGL-20/WNT. We propose that UNC-52 serves dual roles in C. elegans larval development in the maintenance of muscle structure and the regulation of growth factor-like signaling pathways.     

Perlecan displays variable spatial and temporal immunolocalisation patterns in the articular and growth plate cartilages of the ovine stifle joint

Perlecan is a modular heparan sulphate and/or chondroitin sulphate substituted proteoglycan of basement membrane, vascular tissues and cartilage. Perlecan acts as a low affinity co-receptor for fibroblast growth factors 1, 2, 7, 9, binds connective tissue growth factor and co-ordinates chondrogenesis, endochondral ossification and vascular remodelling during skeletal development; however, relatively little is known of its distribution in these tissues during ageing and development. The aim of the present study was to immunolocalise perlecan in the articular and epiphyseal growth plate cartilages of stifle joints in 2-day to 8-year-old pedigree merino sheep. Perlecan was prominent pericellularly in the stifle joint cartilages at all age points and also present in the inter-territorial matrix of the newborn to 19-month-old cartilage specimens. Aggrecan was part pericellular, but predominantly an extracellular proteoglycan. Perlecan was a prominent component of the long bone growth plates and displayed a pericellular as well as a strong ECM distribution pattern; this may indicate a so far unrecognised role for perlecan in the mineralisation of hypertrophic cartilage. A significant age dependant decline in cell number and perlecan levels was evident in the hyaline and growth plate cartilages. The prominent pericellular distribution of perlecan observed indicates potential roles in cell-matrix communication in cartilage, consistent with growth factor signalling, cellular proliferation and tissue development.     

Disruption of perlecan binding and matrix assembly by post-translational or genetic disruption of dystroglycan function

Dystroglycan is a cell-surface matrix receptor that requires LARGE-dependent glycosylation for laminin binding. Although the interaction of dystroglycan with laminin has been well characterized, less is known about the role of dystroglycan glycosylation in the binding and assembly of perlecan. We report reduced perlecan-binding activity and mislocalization of perlecan in the LARGE-deficient Large(myd) mouse. Cell-surface ligand clustering assays show that laminin polymerization promotes perlecan assembly. Solid-phase binding assays provide evidence for the first time of a trimolecular complex formation of dystroglycan, laminin and perlecan. These data suggest functional disruption of the trimolecular complex in glycosylation-deficient muscular dystrophy.     

chinmo-mutant spermatogonial stem cells cause mitotic drive by evicting non-mutant neighbors from the niche

1. Download : Download high-res image (175KB)
2. Download : Download full-size image

     

Perlecan Binds to the β-Amyloid Proteins (Aβ) of Alzheimer's Disease, Accelerates Aβ Fibril Formation, and Maintains Aβ Fibril Stability

Abstract: Perlecan is a specific heparan sulfate proteoglycan that accumulates in the fibrillar β-amyloid (Aβ) deposits of Alzheimer's disease. Perlecan purified from the Engelbreth-Holm-Swarm tumor was used to define perlecan's interactions with Aβ and its effects on Aβ fibril formation. Using a solid-phase binding immunoassay, freshly solubilized full-length Aβ peptides bound immobilized perlecan at two sites, representing both high-affinity [K_D = ～5.8 × 10^?11M for Aβ (1–40); K_D = ～6.5 × 10^?12M for Aβ (1–42)] and lower-affinity [K_D = 3.5 × 10^?8M for Aβ (1–40); K_D = 4.3 × 10^?8M for Aβ (1–42)] interactions. An increase in the binding capacity of Aβ (1–40) to perlecan correlated with an increase in Aβ amyloid fibril formation during a 1-week incubation period. The high-capacity binding of Aβ (1–40) to perlecan was similarly observed using perlecan heparan sulfate glycosaminoglycans and was completely abolished by heparin, but not by chondroitin-4-sulfate. Using a thioflavin T fluorometry assay, perlecan accelerated the rate of Aβ (1–40) amyloid fibril formation, causing a significant increase in Aβ fibril assembly over a 2-week incubation period at 1 h (2.8-fold increase), 1 day (3.6-fold increase), and 3 days (2.8-fold increase) in comparison with Aβ (1–40) alone. Perlecan also initially accelerated the formation of Aβ (1–42) fibrils within 1 h and maintained significantly higher levels of Aβ (1–42) thioflavin T fluorescence throughout a 2-week experimental period in comparison with Aβ (1–42) alone, suggesting perlecan's ability to maintain amyloid fibril stability. Perlecan's effects on Aβ (1–40) fibril formation and maintenance of Aβ (1–42) fibril stability occurred in a dose-dependent manner and was also mediated primarily by perlecan's glycosaminoglycan chains. Perlecan was the most effective enhancer and accelerator of Aβ fibril formation when compared directly with other amyloid plaque components, including apolipoprotein E, α₁-antichymotrypsin, P component, C1q, and C3. This study, therefore, demonstrates that perlecan not only binds to the predominant isoforms of Aβ, but also accelerates Aβ fibril formation and stabilizes amyloid fibrils once formed, confirming pivotal roles for perlecan in the pathogenesis of Aβ amyloidosis in Alzheimer's disease.